AI Marketplaces Leaderboard

Amass

ChatGPT plugin

Life sciences intelligence

View in ChatGPT directory
Featured
No

not on the featured shelf

Movement

From our daily snapshots over the last 30 days.

Rank by placement

#655of 6,0228places down24h49places down7d
#267#373#479#585Sep 13Sep 19Sep 25Oct 1Oct 7Oct 12

Rank in Education & research

#53of 402024h1places down7d
#42#45#48#51#54Sep 13Sep 19Sep 25Oct 1Oct 7Oct 12

In its category

How this plugin compares with others in the same category. Positions are counted within the category, not across the whole directory.

Education & research53rd of 402 by placement
#PluginPosition7d
50Course Studio#62844places down
51Studyportals#64721places down
52Patent Connector#6497places down
53AmassThis page#65549places down
54PaperDock#6929places up
55Trivana Study — Quiz My Notes#707269places up
56TriviaQuiz#70943places down

All 402 Education & research plugins

Also on other marketplaces

Amass connects your assistant to six curated biomedical corpora: BioMedCore (43M+ records: peer-reviewed publications from PubMed/PMC and conference abstracts from society meetings), TrialCore (1.2M+ clinical trials from ClinicalTrials.gov and the WHO ICTRP), DrugCore (22K+ harmonized drugs/molecules covering modality, clinical stage, structure, synonyms, and the gene targets each drug acts on; ChEMBL-linked), RegulatoryCore (7K+ unified FDA + EMA marketing authorizations with source documents such as labels, reviews, SmPCs, and EPARs), GeneCore (43K+ harmonized human genes with a target-intelligence layer covering druggability, DepMap essentiality, ChEMBL target class, clinical-precedent tractability, curated safety liabilities, and gnomAD constraint), and PatentCore (preview, life-science patents with full-text search, CPC/IPC classifications, assignees/inventors, and patent families). Users can search and retrieve full records with filters that beat open-web retrieval, and follow cross-links across corpora back to each underlying source.

Example prompts

  • “Map the current landscape for oral GLP-1 agonists in obesity — what's approved, what's in trials, and who holds patents.”
  • “Make the case for and against KRAS G12D as a drug target: biology, what's been tried clinically, and failures.”
  • “What happened to semaglutide since first approval — indication expansions, label changes, safety signals, and literature.”
Categories
Made by
Amass Technologies ApS · Website
Sign-in
On Install
Availability
Available
Version
7.0.0
Created
June 4, 2026
More info